­

Investor Presentations

Advaxis, Inc.  a late-stage biotechnology company developing cancer immunotherapies, held that its annual Investor & Analyst Day on Monday, June 12, 2017.

Please view the archived webcast

Presentations focused on Patients, Partnerships and Progress, providing updates on the company’s Lm Technology™ and nine development programs. Several clinical investigators shared their experiences and case studies during this year’s event, including:

  • Sharad Ghamande, MD, an associate professor and Director of Gynecologic Oncology at the Georgia Cancer Center at Augusta University, who is a principal investigator in Advaxis’ Phase 1 study of axalimogene filolisbac evaluated at higher doses in women with metastatic cervical cancer.
  • Cathy Eng, MD, FACP, who is a professor and the Associate Medical Director, Colorectal Center, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. Dr. Eng is the principal investigator in Advaxis’ Phase 2 FAWCETT study, evaluating axalimogene filolisbac in patients with metastatic anal cancer.
  • Nicola Mason, PhD, BVetMed, an associate professor of medicine and pathobiology at the University of Pennsylvania School of Veterinary Medicine, specializing in canine cancer, is an investigator evaluating ADXS-HER2 in dogs with surgically treated osteosarcoma.
  • Brian Slomovitz, MD, who is the Director of the Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Miami Miller School of Medicine, as well as Co-leader of the Gynecologic Cancers Site Disease Group at Sylvester Comprehensive Cancer Center. Dr. Slomovitz is a co-principal investigator on the company’s Phase 3 AIM2CERV trial in high-risk, locally advanced cervical cancer and an investigator evaluating axalimogene filolisbac in combination with AstraZeneca’s durvalumab in metastatic cervical cancer.
  • Mark Stein, MD, a medical oncologist at the Rutgers Cancer Institute of New Jersey, working across multiple disciplines in the Prostate Cancer Program and the Urologic Oncology Program, is an investigator in a Phase 1/2 trial evaluating ADXS-PSA in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC).

Advaxis senior management also shared details on the company’s clinical development, the collaboration with Amgen, Inc. on ADXS-NEO and plans for regulatory submission and commercialization. Advaxis presentations included:

  • Robert Petit, PhD, discussing axalimogene filolisbac and a potential prognostic biomarker, and preclinical work with Lm-WT1, ADXS-NEO and ADXS-HOT
  • Mayo Pujols, discussing details of the IND for ADXS-NEO
  • Fatima Ahmad, PharmD, sharing a publication and congress overview
  • Bob Ashworth, PhD, providing a EU regulatory approval update
  • Chris Duke presenting Advaxis’ plan for EU commercial readiness